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Title: Repetitive Transcranial Magnetic Stimulation (rTMS) for depression: outcomes in a 
United Kingdom (UK) clinical practice 
Abstract  
Objective: 
The aim of this paper is to present the outcomes data from the largest United Kingdom’s 
(UK) National Health Service (NHS) clinical rTMS service treating treatment resistant 
depression (TRD). 
Methods 
The study was a retrospective investigation of routinely collected data on patients receiving 
rTMS between 2015 and 2017. Measures used were the clinician-rated Clinical Global 
Impression (CGI) and Hamilton Depression Rating Scale (HAM-D), and patient rated Beck 
Depression Inventory (BDI). The outcome data of 73 patients with TRD was analysed. The 
sample included patients with co-morbid psychiatric diagnosis. 
Results 
Response and remission rates respectively were 40.4% and 25.5% for the HAM-D; 35.6% 
and 20.8% for the BDI; and 51.1% and 52.1% for the CGI. Effect sizes were medium (.54, 
.52 and .56 respectively). 
Conclusions 
The results show that a UK based clinical service achieves similar results to those published 
internationally and that clinical rTMS can have significant impact on symptoms of depression 
in many patients with TRD. Health services are under pressure to make financial savings, 
investment in rTMS could reduce the long term treatment costs associated with TRD.  
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Major depressive disorder (clinical depression) is the leading cause of disability worldwide, 
and is a major contributor to the overall global burden of disease (WHO, 2017). The causes 
of depression vary at an individual level and can be a result of a complex interaction of 
social, psychological and biological factors. Depression can result in emotional, 
psychological and functional problems that can be detrimental to the well-being and health of 
those affected and their friends and family (WHO, 2017). Depression carries a large cost to 
society through care and treatment costs and the loss of productivity and societal 
contribution of those affected (Greenberg et al., 2015). Even where pharmacological and 
psychological treatment is available, not everyone will find they are effective for them; 
relapse rates remain significant, underscoring the chronicity of depressive disorders (Huynh 
& McIntyre, 2008) 
There is no single accepted definition of what constitutes treatment resistant depression 
(TRD) (Berlim & Turecki, 2007). A study in the US reported over 50% of people did not 
experience remission after first-line antidepressant treatment, and one-third did not 
experience remission after four different courses of treatment (Rush et al., 2006). A multi-site 
study in Europe reported that 50% of people did not respond to two consecutive courses of 
antidepressant treatment (Souery et al., 2008). The non-response rate to psychotherapy, 
most commonly cognitive behavioural therapy (CBT), has been reported as being 70% 
(Griffiths & Griffiths, 2015). Therefore, many people do not respond to ‘standard’ treatments 
that are generally available in first world economies, and some who do respond initially may 
relapse and become unresponsive to subs quent treatment.  
A relatively new treatment being offered by state and private healthcare providers is 
repetitive transcranial magnetic stimulation (rTMS). This is a form of neuromodulation: a 
non-invasive and non-convulsive technique where a purpose‑made electromagnetic coil is 
placed against the patient’s scalp to deliver a short, powerful magnetic field pulse to induce 
electric currents in the cerebral cortex (Hardy et al., 2016). rTMS treatment usually 
comprises daily sessions lasting about 30 minutes, over a period which is typically for 4 to 6 
weeks (Hardy et al., 2016). Evidence suggests that rTMS results in changes in brain activity, 
metabolism and connectivity that relate to emotional processing (Kito S, Fujita K, & Koga, 
2008). However, as with many forms of antidepressant treatment the exact mechanism of 
treatment action is unknown (Hardy et al., 2016). 
In the United States the Food and Drug Administration (FDA) approved TMS for treatment of 
depression in 2008 (Janicak & Dokucu, 2015). In the UK, the National Institute for Health 
and Care Excellence (NICE) (IPG 542, 2015) appraised the evidence for rTMS in treatment 
resistant depression (TRD) and found it to be safe and effective in reducing depressive 
symptoms compared to sham TMS, and that treatment does not require either hospital 
admission or anaesthesia (NICE, 2015). Treatment can be carried out on an outpatient basis 
and rTMS was recommended for the treatment of depression, including TRD.  NICE (IPG 
542, 2015) noted that reports from patients about the treatment were positive, and patients 
described significant benefits to their quality of life, including some no longer taking oral 
antidepressant medications (NICE, 2015). A systematic review of 45 RCTs found rTMS to be 
robustly effective versus sham TMS on depression symptoms, response or remission; and 
that patients undergoing rTMS are twice as likely to achieve clinical response or remission 
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compared to a sham procedure (Health Quality Ontario, 2016). Yesavage et al (2018) found 
that 39.0% of war veterans in an rTMS RCT experienced remission, but there was no 
difference in remission rates between the active and sham treatments. However, this trial 
included participants with comorbid PTSD and/or substance abuse and the population was 
largely male (and so not representative of general TRD population); as Nemeroff (2018) 
states, placebo rates can be a major issue in depression research. A recent review found 
that placebo response in rTMS depression trials was large, suggesting that excluding 
placebo responders with a run-in phase may not confer advantage, since response to rTMS 
may decrease as well (Razza et al. 2018). Placebo response may be a component of 
therapeutic response to rTMS, and placebo response increase over time could indicate need 
for improvement in rTMS trial designs, including better sham versions of rTMS (Razza et al. 
2018). 
In research trials, response and remission rates have ranged between 25–50% and 12–35% 
respectively. (Allan, Herrmann, & Ebmeier, 2011; Berlim et al. 2014; Gross, Nakamura, 
Pascual‐Leone, & Fregni, 2007; Herrmann & Ebmeier, 2006; Kozel & George, 2002; Lam, 
Chan, Wilkins-Ho, & Yatham, 2008; Schutter, 2010; Slotema, Dirk Blom, Hoek, & Sommer, 
2010; Xie, Chen, & Wei, 2013). Following initial FDA clearance in 2008, a number of peer 
review published studies have reported remission and therapeutic response in clinical 
service settings. Response and remission rates have ranged between 29–51% and 6–37% 
respectively (Carpenter et al, 2012; Connolly et al. 2012; Galletly, Clarke, Carnell, & Gill, 
2015; Taylor et al., 2017).   
There is considerable research evidence for the effectiveness of repetitive transcranial 
magnetic stimulation in the treatment of depression from research trials. However, there has 
been a lack of information on outcomes from UK clinical practice. This is the first study to 
report the patient characteristics and outcomes data from a service delivering rTMS within 




The study was a retrospective investigation of routinely collected data on patients receiving 
rTMS services between 2015 and 2017 at a UK based service provider. Demographic 
information (gender, age at admission), diagnosis, treatment funder, and outcomes data 
were extracted from clinical records containing routinely collected data. Analysis was 
conducted using an anonymised database or routinely collected data and so ethical approval 
was not required. 
Measures 
The Hamilton Depression Rating Scale (HAM-D) is one of the most commonly used and 
extensively studied measures of depressive symptoms (Hamilton, 1960). Internal, inter-rater 
and retest reliability estimates are adequate for the global score (Hamilton, 1960; Bagby, 
Ryder, Schuller, & Marshall, 2004). The 2 item version was used, first 17 items scored. The 
Beck Depression Inventory (BDI) is one of the most widely used measures of depression 
severity (Beck & Alford, 2009). The scale has high content validity, construct validity, 
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concurrent validities, content validity internal consistency, and reliability (Jackson-Koku, 
2016). The Clinical Global Impression score (CGI) rating scale is one of the most widely 
used assessment instruments in psychiatry (Guy, 1976). The Clinical Global Impression 
Scale (CGI) is a brief clinician-rated instrument of illness severity. There is a lack of strong 
evidence for the validity and therefore it is recommended as part package of assessments 
(Forkmann et al. 2011). The measures were collected prior to treatment and shortly following 
final first course of treatment.  
Process to treatment  
Patients with depressive symptoms are referred to the service by their GP or psychiatrist. A 
medical and physical history is taken and patients are then assessed for a diagnosis of TRD 
by a psychiatrist working in the neuromodulation unit. TRD is defined as non-response to 2 
or more appropriate courses of anti-depressants.  rTMS protocol and length of treatment are 
set by the psychiatrist. Patients who lack capacity to consent to treatment are excluded. 
Patients are provided with information about the treatment (procedures, risks, side effects, 
remission/response rates) and are required to sign a ‘consent to treatment’ form; they can 
withdraw consent at any point. rTMS equipment supplier is Magstim. 
rTMS treatment 
The site of stimulation is be determined using the min-R “10-20” method with stimulation at 
the F5 electrode (Tsuzuki et al. 2016).  The majority of patients (n = 68, 93.2%) received of 
FDA (Food and Drug Administration, 2011) depression protocol high frequency stimulation to 
left dorsolateral prefrontal cortex. Five (6.8%) received Hadley et al. (2011) depression 
protocol high frequency stimulation to left dorsolateral prefrontal cortex.  Of these, 18 
(24.7%) patients with depression and generalised anxiety (as measured with the GAD-7 
[Spitzer et al. 2006]) additionally received right DLPFC inhibitory rTMS (Dilkov et al. 2017), 
immediately prior to delivery of FDA left dorsolateral prefrontal cortex depression treatment. 
This additional treatment option was added to the service in October 2016. The average 
strength of magnetic field was 63.84% (SD= 6.224, range: 43 – 75). During this period there 
were no seizures and two syncopal episodes. Analysis 
Analysis of change from baseline to post first course treatment scores was carried out using 
data from 73 patients. Not all patients had data sets for all depression measures and so 
numbers per measure vary. For categorical responses, we defined treatment response as a 
50% or greater drop on the last assessment of treatment. Partial response was defined as a 
25-50% drop on the last assessment. Remission was defined as CGI-S score as ≤ 2, BDI ≤ 
9 and HAM-D ≤ 7 (Health Quality Ontario, 2016; Connolly et al. 2012; Galletly, Clarke, 
Carnell, & Gill, 2015). 
As the continuous variables were not normally distributed, Wilcoxon signed-rank tests (Z) 
were used to compare baseline with post-treatment measures, together with the calculated 
effect sizes. Using non-parametric analysis (Pearson chi square test and Mann-Whitney U 
test), the differences in demographic variables and between responders and non-responders 
on a number of variables were explored.  All tests were 2-sided, at 1% level of statistical 
significance. Spearman’s rho was used to calculate correlations. Data were analysed using 
statistics software package SPSS.  
 
Page 5 of 13
URL: http://mc.manuscriptcentral.com/ijpcp  Email: IJPC-peerreview@journals.tandf.co.uk


































































The data was collected on a sample of 73 patients with TRD, who were treated between 
January 2015 and October 2017, see table 1. Cross tabulation indicated that female patients 
were overrepresented [χ2 (1) = 6.041, p = .014]. There were no differences between HAM-D 
responders and non-responders in age (N = 73, U = 106.0, p = .175) or gender (N = 73, χ2 = 
0.147, p = .701). Similarly, there were no differences in age and gender between responders 
and non-responders as measured by the CGI and BDI scores.  
Table 1. Demographic characteristics of the sample (n = 73). 
 
Co-morbid diagnosis was as follows: generalized anxiety disorder (GAD) (n = 33, 42.5%); 
bipolar affective disorder (n=10, 13.7%); psychosis (n = 4, 5.5%); emotionally unstable 
personality disorder, autism spectrum disorder (ASD), chronic fatigue syndrome, bulimia 
nervosa (n = 3, 4.1%); post-traumatic stress disorder (PTSD), alcohol dependence (n = 2, 
2.8%); chronic pain syndrome, cocaine dependence, schizoaffective disorder, dysthymia, 
fibromyalgia, mixed and other p rsonality disorder, narcissistic personality disorder, 
obsessive-compulsive disorder, Parkinson's disease, social phobia generalised, intentional 
self-harm (n = 1, 1.4%).  
 
rTMS Treatment Outcome  
 
The average number of rTMS sessions across acute phase was 26.68 (SD = 9.451, range: 
10-60). An average baseline depression scores was in the moderate-severe range at the 
baseline (Table 2).  There was a statistically significant improvement on all depression 
measures after the rTMS treatment, with medium effect sizes. 
 
 
Table 2. Mean pre- and post-treatment scores and mean change in scores  
 
 
Categorical Response and Remission Rates 
The highest response and remission rates were elicited by the CGI, then HAM-D and finally 
BDI (see Table 3). However, the highest partial response was elicited by the HAM-D, then 
CGI and finally BDI. There was a statistically significant positive correlation (p < .001) 
between all three measures: .356 between HAM-D and BDI; .369 between HAM-D and CGI; 
and .519 between CGI and BDI. Using binary logistic regression to explore whether age or 
sex was a predictor of response and remission rates yielded no statistically significant 
predictors of the primary outcome. 
Table 3. Response, partial response and remission rates (%)  
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The results show that rTMS delivered in a UK based clinical service is effective. The 
outcomes are comparable to published RCTs and service data. (Carpenter et al, 2012; 
Connolly et al. 2012; Galletly, Clarke, Carnell, & Gill, 2015; Health Quality Ontario, 2016; 
Taylor et al., 2017) This indicates the effectiveness of NHS delivered rTMS and the need to 
increase availability to enable more people with TRD to potentially benefit. 
In comparing our results with other published service data, the HAM-D remission rates at 
25.5% were higher than one study (20%) but lower than two others (28% and 35.3%); 
however, the response rates at 40.4% were very similar or better than three published 
studies (Carpenter et al, 2012; Connolly et al. 2012; Galletly, Clarke, Carnell, & Gill, 2015). 
In terms of the BDI results, remission and response rates at 20.8% and 35.6% respectively 
were almost identical to published service data (Connolly et al. 2012). The CGI remission 
rates of 52% and response rates of 51.1% were better than published data (Connolly et al. 
2012; Taylor et al., 2017).  
It is not possible to say with certainty why these differences exist, the contribution of 
differences in patient or service factors could be the subject of further investigation. The 
differing length of the treatment could be a factor; there is no gold standard as to how long 
the treatment should last, clinical judgment (usually made in consultation with the patient) is 
used to determine when to end treatment. 
There can be a number of reasons for the differences in response and remission rates seen 
between the measures. For example, correlations between the measures were found to be 
moderate; different scales may pick up different factors in depression; and have differing 
sensitivity to the effects of the treatment may contribute to the varying degrees of response 
and remission rates. One of measures was patient completed (BDI) and two clinician 
completed (CGI & HAM-D), and the assessment of the level of depression symptoms by the 
patient can differ to that of the clinician. 
Participants in clinical trials tend to be narrowly defined in terms of diagnosis. The UK based 
service which is the basis of this paper assesses people as having TRD without excluding 
those with co-morbid psychiatric diagnosis. The outcome results indicate that this approach 
is effective in targeting depression irrespective of the existence of co-morbid mental illness. 
This offers hope to the many people with complex mental health histories who experience 
clinical depression that has not responded to other treatments.  
rTMS could reduce long term health and social care costs associated with TRD. Clinical 
depression incurs £17 billion per year UK service costs (2007 figures) and this is estimated 
to rise to £2 billion (2007 prices) in 2026 (McCrone et al. 2008) Around 75% of these costs 
are attributable to treatment resistant depression (TRD) (Mrazek, Hornberger, & Altar, 
Degtiar, 2014). People with persistent depression seen in a specialist depression service 
offering NICE recommended psychotherapy and pharmacotherapy incur costs of £7-8,000 a 
year (Morriss et al. 2016). Between 12%–20% of depressed patients have TRD, and having 
TRD results in greater loss of economic contribution (Eaton et al. 2008; Nemeroff, 2007). 
Cost-benefit analysis is required to understand the potential savings that could be derived by 
the wider implementation of rTMS services for people with TRD. 
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Further research is required as to why some people respond and others do not and what 
factors determine response. This research is vital due to the financial cost and the treatment 
delivery time involved in undergoing a course of rTMS treatment. 
Limitations  
Data was extracted from a clinical database and patient notes with some missing 
assessments, evidenced by the different number of subjects available for analysis on each 
outcome measure. Treatment was open label and adjunct to any existing antidepressant 
treatments, with the absence of a control. Data was from single site in the UK limiting 
generalizability, however; patients were from across the UK, partially negating this. Females 
were overrepresented and so the results are less generalizable to males. 
Conclusions 
This study adds to the findings of other published service data that outpatient delivered 
rTMS clinical is effective. Further work is needed to define the role of rTMS in a depression 
pathway. This work needs to understand when it is best to offer rTMS in people’s experience 
of depression and when rTMS is a better option than other treatment options such as 
switching antidepressants or ECT. The authors view is that due to low side effects and lack 
of a need for a general anaesthetic that it should be considered in advance of using ECT. 
The availability of rTMS is currently limited. The results support wider availability of rTMS as 
a treatment option for people with TRD. Ideally, rTMS should be a treatment option which is 
freely available to people with TRD who meet the criteria for treatment rather than just those 
who can afford the costs of private treatment. Training in rTMS delivery and advice on 
service set up of rTMS services is essential in expanding availability.  
 
Key points 
- Clinical practice delivered rTMS can have significant impact on symptoms of 
depression in patients with TRD 
- rTMS is effective in treating depression irrespective of the existence of co-morbid 
mental illness 
- rTMS should be a treatment option which is freely available to people with TRD who 
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Table 1. Demographic characteristics of the sample (n = 73). 
Characteristic  
Age, Mean ± SD (Min-Max) 49.10  ± 16.01 (19-80) 
Sex, n (%)  
     Male 26 (35.6) 
     Female 47 (64.4) 
Funding, n (%)  
     NHS 59 (80.8) 
     Private 14 (19.2) 
Treatment, n, Mean ± SD (Min-
Max) 
 
     Depression 65, 24.12 ± 6.69 (10-40) 
     Anxiety 14, 12.36 ± 8.47 (4-30) 
Strength of magnetic field (%), 
Mean ± SD (Min-Max) 
 
     Depression 63.84 ± 6.22 (43 – 75) 
     Anxiety 61.25 ± 2.26 (60 – 65) 
Protocol used, n (%)  
     Standard FDA 68 (93.2) 
     Hadley 2011 5 (6.8) 
 




N Mean ± SD [range] Z p r 
HAM-D 
     Pre 









0.54 21.59 ± 4.99 [9-33] 
11.42 ± 6.52 [0-24] 
CGI 
     Pre 









0.56 4.86 ± 0.92 [3-7] 
2.58 ± 1.16 [0-5] 
BDI      
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     Pre 
     Post 
57 
48 
32.07 ± 10.85 [10-52] 
21.52 ± 13.96 [0-49] 
-5.35 <.000* 0.52 
*Statistically significant p < 0.01. 
 
Table 3. Response, partial response and remission rates (%)  
 Response Partial response No response Remission 
HAM-D 40.4 32.7 26.9 25.5 
CGI 51.1 27.7 21.3 52.1 
BDI 35.6 24.4 40.0 20.8 
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